Switch Therapeutics
South San Francisco, US · Founded 2020 · 8 known investors
Switch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
Founders & leadership
KZ
Kevin ZhangDirector
AI
Alicia Irurzun-LafitteDirector
DM
Dylan MorrisDirector
SH
Si-Ping HanSecretary
DD
Deepshikha DattaChief Executive Officer and President
Investors · 8
Bold Capital PartnersSanta Monica
CRV (Charles River Ventures)Bay Area · $250K – $5M
FREEFLOWBerkeley
Global BrainTokyo · $100K – $184M
Ono Venture Investment, Inc.South San Francisco
Digitalis VenturesreportedNew York · $100K – $10M
Dolby Family VenturesreportedSan Francisco
UCB VenturesreportedBrusselsvia Alicia Irurzun-Lafitte · board
Reported raises · per SEC filings
Form D private placements▶$23.3MraisedNov 2022 · 15 investors · OtherRule 506(b)
▶$23.3MraisedNov 2022 · 15 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Kevin ZhangDirector
- Alicia Irurzun-LafitteDirector
- Dylan MorrisDirector
- Si-Ping HanExecutive Officer
- Deepshikha DattaExecutive Officer, Director
- Offering amount
- $36M
- Amount sold
- $23.3M
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.